The National Cooperative Gallstone Study, a double-masked, placebo-controlled, therapeutic trial of chenodiol (chenodeoxycholic acid), provided an opportunity to study the natural history of cholelithiasis in patients who choose nonsurgical management. The major component of the study comprised 916 patients, 305 of whom were randomly assigned to receive a placebo for 24 months. Among these 305 patients, the probability of having biliary tract pain during the 24 months of prospective evaluation was significantly increased if the patient had had a history of biliary tract pain in the 12 months before entry into the study (69% versus 31%). Thirty-eight percent of patients had stone growth (greater than 0.5 cm3), and 18% had a spontaneous decrease in stone volume. Despite the high incidence of biliary tract pain, nonelective cholecystectomy was required in only 4% of patients during the 24 months.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7326/0003-4819-101-2-171 | DOI Listing |
J Transl Med
January 2025
Department of Psychiatry and Psychotherapy, University Medical Center Mainz, 55131, Mainz, Germany.
Background: Recent research indicates a role of gut microbiota in development and progression of life-threatening diseases such as cancer. Carcinomas of the biliary ducts, the so-called cholangiocarcinomas, are known for their aggressive tumor biology, implying poor prognosis of affected patients. An impact of the gut microbiota on cholangiocarcinoma development and progression is plausible due to the enterohepatic circulation and is therefore the subject of scientific debate, however evidence is still lacking.
View Article and Find Full Text PDFJ Gastroenterol Hepatol
January 2025
Department of Hepatobiliary and Pancreatic Surgery, Fuyang People's Hospital, Fuyang, China.
BMC Gastroenterol
January 2025
Department of Gastroenterology, The First Affiliated Hospital of Shihezi University, No.107 North Second Road, Hongshan Street, Shihezi, 832008, China.
Background: Gallbladder and biliary diseases (GABD) represent prevalent disorders of the digestive system.
Methods: Data on age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life years (DALYs) rate (ASDR) were extracted from the Global Burden of Disease (GBD) 2021 study. The estimated annual percentage change (EAPC) was utilized to quantify temporal trends in GABD.
J Hepatobiliary Pancreat Sci
January 2025
Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan.
Background: High subcutaneous adipose tissue radiodensity (SATr), an indirect surrogate marker of adipose tissue quality, was associated with poor prognosis in various cancers. The present study aimed to assess the association of SATr with survival outcomes in patients with advanced biliary tract cancer (BTC).
Methods: This retrospective, single-center study included patients with unresectable or recurrent BTC who underwent chemotherapy/chemoradiotherapy.
Jpn J Clin Oncol
January 2025
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Background: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity in chemotherapy contributes to confirm generalizability and reliability of the study itself. However, there have been no studies conducted to assess the heterogeneity among participating centers in randomized phase III trials for biliary tract cancer.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!